Cepheid Introduces Xpert GBS LB XC
SUNNYVALE, Calif., Nov. 16, 2022 /PRNewswire/ -- Cepheid today announced the availability of Xpert® GBS LB XC (extended coverage), a molecular diagnostic test for qualitative detection of Group B Streptococcus (GBS) using enriched Lim broth cultures of patient samples. Xpert GBS LB XC builds upon the success of Xpert GBS LB which was launched in 2012. The next-generation test is now available and will begin shipping to US customers in November.